Inhibikase Therapeutics, Inc. is a pharmaceutical company based in Atlanta, GA, specializing in the development of small-molecule kinase inhibitor therapeutics for the treatment of Parkinson's disease, other neurodegenerative diseases, and neurological infections. With a novel understanding of the mechanism of Parkinson's disease and a disruptive approach to designing small-molecule kinase inhibitors, they aim to modify the course of this neurodegenerative disease and potentially alter the pathway of other neurodegenerative diseases caused by misfolded proteins.
Through their robust pipeline, which includes multiple candidates developed using their RAMP drug innovation and prodrug technology engines, Inhibikase Therapeutics is focused on developing disease-modifying therapies that can stop or reverse the effects of neurodegenerative diseases both inside and outside the brain. They are actively conducting clinical trials for Parkinson's disease and offer opportunities for patients to be part of their innovative research.
Generated from the website